Drugs / JBZ-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06801002 | Mar 2025 → Feb 2027 expected | cancer | Jabez Bioscience, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JBZ-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06801002 ↗ |
| Action | Inhibit | “a DHODH inhibitor” NCT06801002 ↗ |
| Route | Oral | “receive 1 dose 5 mg orally.” NCT06801002 ↗ |
| Target | DHODH | “a DHODH inhibitor” NCT06801002 ↗ |